Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Regeneron Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-847-7000 Fax: n/a


Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.

Visit our website –
Check out our openings –

 Key Statistics

Ownership: Public

Web Site: Regeneron Pharmaceuticals, Inc.
Employees: 2300+
Symbol: REGN



Sanofi US 

Bayer Corporation 

Geisinger Health System  Collaboration with Regeneron Genetics Center LLC, wholly-owned subsidiary of Regeneron.

 Company News
Regeneron Pharmaceuticals, Inc. (REGN) To Report First Quarter 2014 Financial And Operating Results And Host Conference Call And Webcast On May 8, 2014 4/11/2014 7:45:03 AM    More...
Robert A. Ingram Elected To Regeneron Pharmaceuticals, Inc. (REGN) Board Of Directors 4/7/2014 6:24:53 AM    More...
Booming Regeneron Pharmaceuticals, Inc. (REGN) Unveils 10 Newly Created Teaching Fellowships 4/4/2014 6:50:16 AM    More...
Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (France) (SAN.PA) Shows Off Positive Phase 2 Alirocumab Data 4/1/2014 7:20:45 AM    More...
Sanofi (France) (SAN.PA) And Regeneron Pharmaceuticals, Inc. (REGN) To Present Alirocumab Clinical Data At The American College of Cardiology's 63rd Annual Scientific Session 3/27/2014 6:53:55 AM    More...
Regeneron Pharmaceuticals, Inc. (REGN)'s Plans To Create 300 High-End Jobs Threatened 3/13/2014 7:26:55 AM    More...
Regeneron Pharmaceuticals, Inc. (REGN),Sanofi (France) (SAN.PA)'s Cholesterol Drug Investigated By FDA For Side Effects 3/10/2014 7:53:13 AM    More...
Bayer HealthCare (BAY) And Regeneron Pharmaceuticals, Inc. (REGN) Announce Regulatory Submission Of EYLEA® (Aflibercept) Injection For The Treatment Of Diabetic Macular Edema In Japan 3/3/2014 10:40:30 AM    More...
Regeneron Pharmaceuticals, Inc. (REGN) Chief Now A Billionaire 2/26/2014 8:42:49 AM    More...
Regeneron Pharmaceuticals, Inc. (REGN) Announces FDA Acceptance Of EYLEA® (Aflibercept) Injection Supplemental Biologics License Application For The Treatment Of Macular Edema Following Branch Retinal Vein Occlusion 2/24/2014 11:46:53 AM    More...